A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy
Recruiting
Celltrion Pharm, Inc.
Phase 4
2020-02-11
The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is
non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin
(HbA1c) change from baseline at Week 52.
A Study to Evaluate the Effect of add-on Pioglitazone or Dapagliflozin in Participants With Type 2 Diabetes Mellitus Inadequately Controlled by Alogliptin and Metformin Therapy
Recruiting
Takeda
Phase 4
2020-02-11
The purpose of this study is to assess the pioglitazone plus alogliptin plus metformin is
non-inferior to dapagliflozin plus alogliptin plus metformin on glycosylated haemoglobin
(HbA1c) change from baseline at Week 52.
Glimepiride, Alogliptin and Alogliptin+Pioglitazone Combination
Active, not recruiting
Seoul National University Hospital
Phase 4
2015-12-31
- This trial is a three-armed, open label, random assignment trial.
- The research subjects are patients who are first starting their treatment or patients
who have failed with the metformin treatment and are changing their medication. They
will be assigned to one of the following treatment groups: the glimepiride monotherapy
treatment group, the alogliptin monotherapy treatment group, and the alogliptin -
pioglitazone combination therapy treatment group
- This trial is a prospective trial which will conduct surveys 6 times over the course of
the 6 months in which each treatment group is administered drugs (Week -2, Baseline,
Week 4, Week 12, Week 24, follow-up safety survey).
- This trial is a multicenter clinical trial which will be conducted at more than 5
general hospital medical institutions in the vicinity of the capital.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
